Clinical trials: Epirubicin
Breast Cancer
Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
Primary Objectives: Determine the impact of each regimen on the disease free and overall survival of patients with operable breast cancer.
- Trial name
- NCT00050167
- Testing
- Paclitaxel, Docetaxel, Capecitabine
- Where
- United States
- Volunteers
- 603 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasm
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer
Evaluation of efficacy of treatment with epirubicin (5 years follow-up). Evaluation of frequency of dose reduction. Evaluation of frequency of neoadjuvant treatment with E(120mg) / C(600mg).
- Trial name
- NCT01061359
- Testing
- Epirubicin: Observational Study
- Volunteers
- 1,981 people
- Sponsor
- Pfizer
Breast Cancer
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer.
- Trial name
- NCT00014222
- Testing
- epoetin alfa, filgrastim, cyclophosphamide
- Where
- 78 sites in United States, Canada
- Volunteers
- 2,104 people
- Sponsor
- NCIC Clinical Trials Group